| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S11775 R43318 |
Richardson, 2019 | Elective termination of pregnancy | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No Matched Monotherapy: no or not specified | 1.02 [0.60;1.68] | 21/281 103/1,405 | 124 | 281 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11792 R43390 |
Ozturk, 2016 | Elective termination of pregnancy | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified | 3.39 [0.68;16.78] C | 2/13 14/275 | 16 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11777 R43336 |
Te Winkel, 2016 | Elective terminations of pregnancy (ETOPs) | during pregnancy (anytime or not specified) | prospective cohort | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified | 2.36 [1.46;3.82] C | 57/732 25/724 | 82 | 732 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11692 R42993 |
Kieler, 2015 | Elective termination of pregnancy (at 12–23 weeks of gestation) | during pregnancy (anytime or not specified) | nested case control | unexposed (general population or NOS) | Adjustment: Yes Matched Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 2.60 [1.80;3.90] | -/- 14,911/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 1.97 [1.19;3.26] | 222 | 1,026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded